Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02778282 · ClinicalTrials.gov registry record · NA

MySafeRx™: An Integrated Mobile Platform for Buprenorphine Adherence

A NA study of Opioid Use Disorder, sponsored by Dartmouth-Hitchcock Medical Center.

Completed
Registry status
NA
Development phase
27
Enrollment target
3
Study locations

NCT02778282: Completed NA study of Opioid Use Disorder, sponsored by Dartmouth-Hitchcock Medical Center.

NCT02778282 is a NA study of Opioid Use Disorder that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 27 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02778282, a NA study of Opioid Use Disorder, has completed, sponsored by Dartmouth-Hitchcock Medical Center.

COMPLETED
Registry status
NA
Development phase
27 participants
Enrollment target
3
Study locations

Study Summary

The goal of the MySafeRx study is to evaluate the feasibility, acceptability, and usability of a novel platform that integrates text messaging reminders, secure electronic pill organizers, and daily remote brief motivational recovery support visits with a standardized protocol for supervised self- administration of buprenorphine via videoconferencing.

Primary Outcome

Feasibility will be demonstrated by MySafeRx achieving supervised self-administration of B/N on \>= 30 out of the first 42 days (equivalent to an average of 5 out of 7 days) for at least 2/3 of subjects randomized to MySafeRx.

Conditions Studied

Interventions

  • OTHER MySafeRx™

Study Locations (3)

Vermont

  • Hawthorn Recovery Center - Bennington
  • Mount Anthony Primary Care - Bennington

Massachusetts

  • Cambridge Health Alliance Outpatient Addiction Services - Somerville

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2017-03-24
Est. Completion 2021-08-31
Phase NA
Dartmouth-Hitchcock Medical Center

427 total trials

What the finished NCT02778282 record still lists

NCT02778282 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which MySafeRx™ is the first listed.

NCT02778282 reports a single indexed study location in Vermont, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02778282 about?

NCT02778282 is a clinical study titled "MySafeRx™: An Integrated Mobile Platform for Buprenorphine Adherence". The goal of the MySafeRx study is to evaluate the feasibility, acceptability, and usability of a novel platform that integrates text messaging reminders, secure electronic pill organizers, and daily remote brief motivational recovery support visits with a standardized protocol for supervised self- a...

What is the current status of trial NCT02778282?

This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2017-03-24. Estimated completion is 2021-08-31.

What conditions does trial NCT02778282 study?

This clinical trial studies the following conditions: Opioid Use Disorder.

What interventions are being tested in trial NCT02778282?

The interventions under investigation include: MySafeRx™ (OTHER).

Who is sponsoring clinical trial NCT02778282?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02778282 being conducted?

This trial has 3 study locations across Massachusetts, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02778282's enrollment target sits among peer trials

27 216th of 257 higher than 42 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00912041 · 27 participants · NA

    BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

  • NCT02847559 · 27 participants · Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

  • NCT03380195 · 27 participants · NA

    Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness

  • NCT03384238 · 27 participants · Phase 1

    Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02778282, the US trial registry maintained by the National Library of Medicine. NCT02778282 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.